CQ Medical

Mentabinol® Spray
or Syringe method

THC Patented Formula developed for Anxiety, Depression, and PTSD

“A safer alternative to all other THC Products”

Developed by Dr. Steven Laviolette, Professor and Neuroscientist, and his scientific team at Western University, London, Ontario Canada

MENTABINOL® – New disruptive formula based on science and pre-clinical trials

  • Developed for Anxiety, Depression and PTSD.
  • Provides safer alternative to all other THC products, protecting users from negative psychiatric side-effects caused by THC consumption
  • Reduces inflammation, thus, is anticipated to be beneficial for pain management.

Pre-clinical results

  • Reversal of depression-like and schizophrenia related symptom effects.
  • Complete blockage of memory impairment.
  • Complete blockage of hyperactive activity.
  • Complete blockage of gene vulnerability.

Bioavailability is extremely critical for effective medical cannabis delivery

  • The bioavailable formula and the sublingual  delivery system provide quicker onset and high absorption (90%) of the active ingredients.

Accurate volume sprayed under the tongue or dispense accurate volume using supplied syringe No guesswork and dose measuring

  • Eliminates contamination and oxidation (always closed to the environment

About Dr. Steven Laviolette:

Professor and Neuroscientist at the Schulich School of Medicine & Dentistry at Western University in London, Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status. Dr. Laviolette’s research team has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the world’s top tier of neuroscience and psychiatry journals. The following is a link to Dr. Laviolette’s profile on Western University’s website.

http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html